Oxygen Sparing Effect of Bacteriotherapy in COVID-19
Prospective analysis of 69 severe COVID-19 patients requiring non-invasive oxygen therapy, 40 treated with probiotic formulation SLAB51, showing lower oxygen requirements and higher blood levels of pO2, O2Hb and SaO
2 with treatment. Authors suggest that enzymes in SLAB51 could reduce oxygen requirements in intestinal cells, resulting in more oxygen available for other organs.
The immune effects of probiotics are strain-specific.
Although the 70% lower mortality is not statistically significant, it is consistent with the significant 61% lower mortality
[37‑76%] from meta analysis of the
8 mortality results to date.
risk of death, 70.4% lower, RR 0.30, p = 0.42, treatment 0 of 40 (0.0%), control 1 of 29 (3.4%), NNT 29, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
risk of ICU admission, 81.9% lower, RR 0.18, p = 0.15, treatment 1 of 40 (2.5%), control 4 of 29 (13.8%), NNT 8.9.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Ceccarelli et al., 23 Aug 2021, prospective, Italy, peer-reviewed, 10 authors.
Abstract: nutrients
Article
Oxygen Sparing Effect of Bacteriotherapy in COVID-19
Giancarlo Ceccarelli 1 , Massimiliano Marazzato 1, *, Luigi Celani 1 , Francesca Lombardi 2 , Alessandra Piccirilli 3 ,
Massimo Mancone 4 , Vito Trinchieri 1 , Francesco Pugliese 5 , Claudio M. Mastroianni 1 and Gabriella d’Ettorre 1
1
2
3
4
5
*
Citation: Ceccarelli, G.; Marazzato,
M.; Celani, L.; Lombardi, F.; Piccirilli,
A.; Mancone, M.; Trinchieri, V.;
Pugliese, F.; Mastroianni, C.M.;
d’Ettorre, G. Oxygen Sparing Effect of
Bacteriotherapy in COVID-19.
Nutrients 2021, 13, 2898. https://
doi.org/10.3390/nu13082898
Academic Editor: Leyuan Li
Department of Public Health and Infectious Diseases Sapienza, University of Rome, 00185 Rome, Italy;
giancarlo.ceccarelli@uniroma1.it (G.C.); luigi.celani@uniroma1.it (L.C.); vito.trinchieri@uniroma1.it (V.T.);
claudiomaria.mastroianni@uniroma1.it (C.M.M.); gabriella.dettorre@uniroma1.it (G.d.)
Department of Life, Health & Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy;
francesca.lombardi@univaq.it
Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, Italy;
alessandra.piccirilli@univaq.it
Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences Sapienza, University of Rome,
00185 Rome, Italy; massimo.mancone@uniroma1.it
Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, 00185 Rome, Italy;
francesco.pugliese@uniroma1.it
Correspondence: massimiliano.marazzato@uniroma1.it
Abstract: Background: We previously reported that severe COVID-19 patients had higher chances of
survival and a reduced risk of developing respiratory failure when administered with the probiotic
formulation SLAB51. This study aimed to investigate further bacteriotherapy mechanisms and
how early they are activated. Methods: We performed an analysis on the blood oxygenation
parameters collected in sixty-nine severe COVID-19 patients requiring non-invasive oxygen therapy
and presenting a CT lung involvement ≥50%. Twenty-nine patients received low-molecular-weight
heparin, azithromycin and Remdesivir. In addition, forty subjects received SLAB51. Blood gas
analyses were performed before the beginning of treatments and at 24 h. Results: The patients
receiving only standard therapy needed significantly increased oxygen amounts during the 24 h
observation period. Furthermore, they presented lower blood levels of pO2 , O2 Hb and SaO2 than the
group also supplemented with oral bacteriotherapy. In vitro data suggest that SLAB51 can reduce
nitric oxide synthesis in intestinal cells. Conclusions: SARS-CoV-2 infected patients may present
lesions in the lungs compromising their gas exchange capability. The functionality of the organs
essential for these patients’ survival depends mainly on the levels of pO2 , O2 Hb and SaO2 . SLAB51
contains enzymes that could reduce oxygen consumption in the intestine, making it available for the
other organs.
Received: 11 July 2021
Accepted: 21 August 2021
Keywords: COVID-19; SLAB51; probiotics; nitric oxide; hypoxia
Published: 23 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit